Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a severe debilitating genodermatosis characterised by severe blistering of the skin, chronic morbidity and predisposition to malignancy. This autosomal recessive disorder is caused by mutations in the type VII collagen gene (COL7A1), resulting in loss of expression of type VII collagen protein essential for the anchoring of the epidermis to the dermis. To date, developed cell based therapies have included intradermal allogeneic fi broblast injections and allogeneic bone marrow stem cell therapy. We have been investigating ex-vivo correction of autologous cells for the treatment of RDEB. A third generation lentiviral vector platform for the delivery of a codon optimised COL7A1 transgene has been designed and constructed. Human COL7A1 deficient keratinocytes and fibroblasts with compound heterozygote mutations were transduced and the reconstitution of COL7A1 expression was evaluated. The restoration of full length 290kda type VII collagen protein was confi rmed by western blot analysis and was detected in both cell lysate and culture medium. The expression was further supported by immunocytofl uorescence staining. Durability of COL7A1 expression was tracked for one month in transdcued cells and results showed stable expression. In addition, three dimensional organotypic cultures generated using transduced RDEB keratinocytes and fi broblasts revealed restoration of the type VII collagen protein at the dermal epidermal junction. Genetically corrected cells were also grafted into a human/murine skin graft model. Biopsies taken from the vector corrected graft at 8 weeks confi rmed deposition of human type VII collagen at the dermal epidermal junction (DEJ) which was entirely absent in the untransduced RDEB control graft. These data suggest that gene therapy using lentiviral corrected autologous cells is a feasible therapeutic approach for RDEB, with systemic delivery forming the next stage of development.
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Reprogramming of Murine Gallbladder Cells towards the Pancreatic β-Cell Fate In Vitro
Yuhan Wang, 1 Ray D. Hickey, 2 Markus Grompe. 1 1 Oregon Stem Cell Center, Oregon Health & Science University, Portland, OR; 2 Mayo Clinic, Rochester, MN. fType I diabetes is characterized by the loss of -cell mass through autoimmune response. The only defi nitive treatment for this disease is ectopic -cells or islets transplantation. However, two major challenges exist: one is the paucity of transplantable material and second is the immune rejection of transplanted cells. Therefore, an intense search for an abundant autologous cell source for -cell transplantation is needed. Adult endoderm derivatives are considered as potential sources for the production of transplantable -cells, as they share genetic and epigenetic proximity with the pancreas. It has already been elegantly demonstrated that in vivo reprogramming of endoderm derivatives, such as exocrine cells or liver Sox9+ cells using adenovirus vectors is possible in the mouse. However, despite advances in optimized designs of these vectors, the substantial immunogenicity and non-specifi city of adenovirus limited their clinical potential. In vitro approaches are intrinsically safer, as the targeted cell population can be selectively manipulated and the functional interrogation of the cells is possible prior to transplantation. From this perspective, the gallbladder, as part of the extrahepatic biliary system, is particularly interesting for in vitro -cell regeneration. The gallbladder is dispensable and can be removed by a minimally invasive procedure. This allows the possibility of obtaining cells from the patient him or herself and thus avoids the immune rejection of transplanted cells. It has been previously shown by our group that gallbladder cells (GBCs) can be reprogrammed to -like cells via transduction of three transcription factors, Pdx1, Neurog3 and MafA. However, this reprogramming process is only partial: fi rst, these reprogrammed cells lack glucose stimulated insulin secretion; besides, although engrafted rGBCs continued to secrete insulin for more than 10 weeks after renal capsule transplantation, they can not reverse hyperglycemia in diabetic mice. These limitations can be explained by the gene expression differences between rGBCs and pancreatic -cells, which is clearly illustrated in our sequencing data. Ptf1a is a master pancreatic transcription factor. It is highly expressed during pancreatic organogenesis, which contributes largely to the pancreatic cell fate determination. Here, we hypothesized that ptf1a will enhance the reprogramming process and result in a more effi cient reprogramming towards the -cell fate. Our preliminary data indicated that induced expression of ptf1a prior to delivery of the three classic transcription factors led to a two-fold increase in reprogramming effi ciency. Gene expression analysis also indicated enhanced expression of some pancreatic-specifi c genes, which were not up-regulated in previous reprogramming protocol. We demonstrated that fetal gene transfer (FGT) at 0.9 gestation (0.9G) achieved therapeutic human Factor IX (hFIX) levels in a macaque model after a single dose of self-complementary AAV8 or AAV5. Intervention at a preimmune gestation may correct earlyonset pathology or enable evasion of the host immune system, in turn facilitating vector re-administration to boost transgene expression. We compare long-term outcomes of early (0.4G) and late (0.9G) FGT during periods of immune naïveté and competence respectively, and examine transgene expression and immune response after postnatal vector challenge. Six macaque fetuses received AAV5-hFIX (1x10 12 vector genomes (vg)/fetus, n=3) or AAV8-hFIX (2x10 12 -1x10 13 vg/ fetus, n=3) systemically at 0.4G and were monitored for at least one year postnatally. Outcomes were compared with seven fetuses injected at 0.9G with 4x10 12 vg/fetus (AAV5, n=3; AAV8, n=4). Four infants were challenged with the same vector used in utero based on sub-therapeutic expression (<1% of normal activity) and absence of anti-AAV antibodies (early-FGT, n=2; late-FGT, n=2). Each received 2x10 11 vg/kg intravenously. Median expression in early FGT (eFGT) AAV8 infants was 6.0-32.4% over the fi rst year, below steady-state levels seen in late AAV8-FGT of 10.2-58.3% (p=0.01). hFIX levels with early AAV5-FGT of 0.02-2.6% were below median levels in late AAV5-FGT of 3.9-19.6% (p<0.0001). Therapeutic hFIX expression was maintained for one year despite a 4-fold weight gain, except in early AAV5-FGT infants where expression stabilised at GENE & CELL THERAPY OF DIABETES, METABOLIC AND GENETIC DISEASES II <1%. Non-neutralising anti-AAV antibodies were detected in both groups, a milder response with eFGT than with late FGT (lFGT). Tissue transduction in eFGT infants was 1-3 log-folds lower than in lFGT infants (p<0.0001). Two eFGT infants were challenged with AAV5 and two lFGT infants were given AAV5 or AAV8. One eFGT infant showed transient increase in hFIX from 0.2% to 4.7% by day 8, stabilising at 2.2% by one month. Expression in the other eFGT infant increased from 0.8% to 2.8% by day 23 before falling abruptly to <1%. Expression in the lFGT AAV5 infant peaked at 2.1% and stabilized at 1.5% by day 25, while hFIX levels in the AAV8 infant remained <1%. Anti-AAV antibody levels increased briefl y after the challenge but remained below the upper limit in all subjects. No animal developed clinical hepatitis. Early FGT is thus less effective than late FGT, but as the immune response is mild and transient this is still a useful strategy that requires optimisation of dose and other factors. Postnatal vector challenge boosted transgene expression in all but one recipient and did not incite a vigorous immune response, suggesting that immune tolerance could be achieved. Further analysis is required to determine the clinical usefulness of this approach. Transplantation of pancreatic islets is an effi cacious therapeutic option for type I diabetes mellitus, however, current supply of donor pancreata is not suffi cient. Therefore, many groups are exploring various types of pluripotent stem and differentiated adult cells for beta cell replacement therapy. Previous studies showed variable success in generating beta-like cells from different cells, including rodent hepatobiliary cells, which in several cases corrected streptozotocininduced hyperglycemia in mice. We hypothesize that organs (such as pancreas, liver, and gallbladder) derived from the same germ layer can be transformed into another cell type of similar developmental origin without the need to revert back to a pluripotent phase. Here, we focused on extrahepatic biliary cells (EHBCs) as potentially renewable and expandable sources of autologous functional pancreatic beta cells. Normal tissue biopsies of gallbladder and cystic duct from human patients were enzymatically treated to obtain disaggregated cells for expansion in a rat mammary tumor feeder cell line. Preliminary in vitro reprogramming of EHBCs after adenoviralmediated expression of PDX1, MAFA, and NEUROG3 showed upregulation in gene expression of insulin and somatostatin, but not in glucagon, NKX6-1, PCSK1, and NKX2-2. Thus, the combination of PDX1, MAFA, and NEUROG3 expression in human EHBCs was not suffi cient to generate bona fi de beta-like cells in vitro. To further determine additional putative reprogramming factors, we determined the baseline gene expression profi les (using RNA-Seq and RT-qPCR) of human EHBCs in culture. Among pancreas-related genes, only PDX1 was detected at moderate levels. Completely absent are the following genes associated with pancreatic endocrine development, specifi cation or maintenance: NEUROG3, MAFA, MAFB, NKX6-1, NKX2-2, PAX4, NEUROD1, INSM1, MNX1, PTF1A and RFX6. These factors will be tested in combination with PDX1, MAFA, and NEUROG3 to determine usefulness in direct reprogramming of human EHBCs. On the other hand, EHBC-upregulated genes that are not represented in mature human pancreatic beta cells may be targeted for silencing. These include genes involved in embryonic development (RNF1AA, nephronectin), cell adhesion molecules, ubiquitinating enzymes (SH3KBP1, SH3RF1), and cellular proliferation. In summary, putative positive and negative regulators will be targeted for overexpression or suppression in combination with the three major beta cell reprogramming factors. Biochemistry, Federal University of São Paulo, São Paulo, Brazil; 2 Genetics, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; 3 Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; 4 Biophysics, Federal University of São Paulo, São Paulo, Brazil. MPSI is a lysosomal storage disorder, which leads to a series of metabolic alterations and compromises correct functioning of organs. Enzyme replacement therapy using the recombinant protein Laronidase™ is currently available, but the immune response against Laronidase and repeated injections weekly are main drawbacks of this therapy. To overcome these negative points, we proposed of using immunosuppressant mesenchymal stem cells (MSC) modifi ed with IDUA (alpha-L-iduronidase) gene carried by Sleeping Beauty system for long-term IDUA expression. In adult IDUA-KO mice 4 millions of MSC modifi ed with SB vectors pT2-CAGGS-IDUA and pCMV-SB100X, which express IDUA and SB transposase, respectively, were injected in the peritoneum. This number of cells used to produce 359.22 ± 108.16 nmol/mg protein/h in vitro, but in vivo the IDUA activity could be detected only in the fi rst day after second injection in the plasma of fi ve animals out of ten: 0.565 U/ml, 1.173 U/ml, 0.995 U/ml, 0.619 U/ml, 1.615 U/ml to treated and 0.241 ± 0.05 U/ml , 3.233 ± 0.890 U/ml IDUA-KO and WT mice, respectively. Even the IDUA gene expression had not supported for long-term, those treated animals had a signifi cant reduction of dermatan sulfate in the spleen, which varied from 50.6 ± 3.7 g/mg of dry tissue in untreated group (n=2) to 17.2 ± 6.5 g/mg of dry tissue in treated animals (n=4), and heparan sulfate in the liver, which reduced from 10.4 ± 1.43 g/mg of dry tissue in untreated group (n=2) to 177.1 ± 2.9 g/mg of dry tissue in treated animals (n=4). To understand the short-term IDUA gene expression in this model, the recombinant protein Laronidase was used as antigen for detection of antibody anti-IDUA in the sera of the treated mice. In all the treated mice, we detected high titers of this antibody. In addition, 5-fold more TNF alpha was present in the sera of these treated animals even six months after the third MSC injection, indicating a high infl ammatory response. These results show high immunogenicity of IDUA and also contest apparently the immune suppression property of MSC in vivo.
Fetal Gene Therapy at Early and Late Gestation: Analysis of Outcomes and Postnatal Vector Challenge in a Macaque Model

Factors Infl uencing Direct Reprogramming of Primary Human Extrahepatic Biliary Cells into Pancreatic beta Cells
Mesenchymal Stem Cells Do Not Prevent
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Propionic acidemia (PA) is an autosomal recessive genetic disease that results in an inability to metabolize certain amino acids and fats. Current treatment involves restricting consumption of these substrates, and in some cases, elective liver transplantation. Deletion of the Pcca gene in mice mimics the most severe forms of the human disease. Pcca-disrupted mice die within 36 hours of birth, making it a diffi cult model with which to test PA therapies. To provide a more tractable adult model of PA, we generated a hypomorphic model of PA using a transgene bearing an A138T mutant of the human PCCA protein. These Pcca-/-(A138T) mice have 2% of wild-type
